NO20004743L - Farmasøytiske blandinger inneholdende irbesartan og et diuretium - Google Patents

Farmasøytiske blandinger inneholdende irbesartan og et diuretium

Info

Publication number
NO20004743L
NO20004743L NO20004743A NO20004743A NO20004743L NO 20004743 L NO20004743 L NO 20004743L NO 20004743 A NO20004743 A NO 20004743A NO 20004743 A NO20004743 A NO 20004743A NO 20004743 L NO20004743 L NO 20004743L
Authority
NO
Norway
Prior art keywords
diuretic
pharmaceutical compositions
compositions containing
containing irbesartan
irbesartan
Prior art date
Application number
NO20004743A
Other languages
English (en)
Other versions
NO310393B1 (no
NO20004743D0 (no
Inventor
Cathy C Ku
Omar L Sprockel
Beth A Rubitski
Divyakant S Desai
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23876256&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20004743(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20004743L publication Critical patent/NO20004743L/no
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of NO20004743D0 publication Critical patent/NO20004743D0/no
Publication of NO310393B1 publication Critical patent/NO310393B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20004743A 1995-06-07 2000-09-22 Farmasöytiske blandinger inneholdende irbesartan og et diuretikum NO310393B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47261895A 1995-06-07 1995-06-07

Publications (3)

Publication Number Publication Date
NO20004743L true NO20004743L (no) 1996-12-09
NO20004743D0 NO20004743D0 (no) 2000-09-22
NO310393B1 NO310393B1 (no) 2001-07-02

Family

ID=23876256

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19962387A NO310495B1 (no) 1995-06-07 1996-06-06 Farmasöytiske blandinger inneholdende irbesartan
NO20004743A NO310393B1 (no) 1995-06-07 2000-09-22 Farmasöytiske blandinger inneholdende irbesartan og et diuretikum

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19962387A NO310495B1 (no) 1995-06-07 1996-06-06 Farmasöytiske blandinger inneholdende irbesartan

Country Status (22)

Country Link
EP (2) EP1275391B1 (no)
JP (1) JP3162626B2 (no)
KR (1) KR100442719B1 (no)
CN (1) CN1149083C (no)
AR (2) AR002350A1 (no)
AT (2) ATE503478T1 (no)
AU (1) AU702651B2 (no)
CA (1) CA2177772C (no)
CZ (1) CZ291532B6 (no)
DE (2) DE69638348D1 (no)
DK (2) DK1275391T3 (no)
ES (2) ES2205000T5 (no)
HU (1) HU229369B1 (no)
IL (1) IL118309A (no)
NO (2) NO310495B1 (no)
NZ (2) NZ286612A (no)
PL (1) PL184893B1 (no)
PT (2) PT747050E (no)
RU (2) RU2210368C1 (no)
SG (1) SG49956A1 (no)
TW (1) TW442301B (no)
ZA (1) ZA964337B (no)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ509378A (en) * 1998-07-20 2003-04-29 Smithkline Beecham Corp Amorphous ammonium salts of eprosartan and pharmaceuticals thereof, useful for blocking angiotensin II receptors and useful for treating hypertension, congestive heart disease and renal failure
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
DK1216038T3 (da) 1999-08-30 2005-12-27 Sanofi Aventis Deutschland Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser
JP4565456B2 (ja) * 1999-11-02 2010-10-20 塩野義製薬株式会社 着色顆粒の色素定着法
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
DE10244681A1 (de) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
JP2009513543A (ja) * 2003-07-16 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング クロルタリドンの組み合わせ
TR200301553A1 (tr) * 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
JP2005126338A (ja) * 2003-10-21 2005-05-19 Boehringer Ingelheim Pharma Gmbh & Co Kg 心不全治療剤
WO2005089720A1 (en) * 2004-03-10 2005-09-29 Ranbaxy Laboratories Limited Valsartan tablets and the process for the preparation thereof
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006013545A1 (en) * 2004-07-28 2006-02-09 Ranbaxy Laboratories Limited Pharmaceutical compositions of irbesartan
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
AU2006318815B2 (en) * 2005-11-17 2010-08-19 Novartis Ag Pharmaceutical composition
PT1806130E (pt) * 2006-01-09 2010-05-11 Krka D D Novo Mesto Composições farmacêuticas sólidas que compreendem irbesartan
DE102006006588A1 (de) * 2006-02-13 2007-08-16 Ratiopharm Gmbh Schnell freisetzende Irbesartan-haltige pharmazeutische Zusammensetzung
KR20090024248A (ko) * 2006-06-12 2009-03-06 쉐링 코포레이션 Ｃｘｃｒ2의 선택적 길항제 또는 ｃｘｃｒ1과 ｃｘｃｒ2 둘다의 선택적 길항제의 약제학적 제형 및 조성물, 및 염증성 질환을 치료하기 위한 이의 사용방법
EP2269583B1 (en) 2006-06-16 2014-08-13 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising hydrochlorothiazide and telmisartan
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
CA2682929A1 (en) * 2007-04-17 2008-10-23 Ratiopharm Gmbh Pharmaceutical compositions comprising irbesartan
JP5683058B2 (ja) * 2007-04-27 2015-03-11 ニプロ株式会社 経口固形製剤及びその製造方法
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
PT2065035E (pt) 2007-11-28 2010-10-04 Lesvi Laboratorios Sl Formulações farmacêuticas contendo irbesartan
CN101327213B (zh) * 2008-06-20 2010-10-13 海南锦瑞制药股份有限公司 厄贝沙坦氢氯噻嗪药用组合物及其制备方法
JP5296456B2 (ja) * 2008-08-26 2013-09-25 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
WO2010075347A2 (en) * 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
EA021317B1 (ru) * 2009-06-30 2015-05-29 Санофи Монослойные таблетки, содержащие ирбесартан и амлодипин, их получение и их терапевтическое применение
WO2011010316A1 (en) * 2009-07-20 2011-01-27 Hetero Research Foundation Pharmaceutical compositions of irbesartan
AU2010316683B2 (en) * 2009-11-09 2015-10-08 Wyeth Llc Tablet formulations of neratinib maleate
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
JP4974255B2 (ja) * 2010-03-16 2012-07-11 塩野義製薬株式会社 アンジオテンシンｉｉ受容体拮抗剤の配合剤
JP5459670B2 (ja) * 2010-05-07 2014-04-02 塩野義製薬株式会社 着色顆粒の色素定着化剤
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
ES2543427T3 (es) * 2010-07-08 2015-08-19 Ratiopharm Gmbh Forma farmacéutica oral de deferasirox
WO2013100112A1 (ja) * 2011-12-28 2013-07-04 ニプロ株式会社 アンギオテンシンｉｉ拮抗作用を有する化合物を含有する固形医薬組成物
DK2851075T3 (da) 2012-05-14 2022-01-31 Shionogi & Co Præparat, der indeholder 6,7-umættet -7-carbamoylmorphinanderivat
CN113842362A (zh) 2012-11-14 2021-12-28 格雷斯公司 含有生物活性材料与无序无机氧化物的组合物
JP5714652B2 (ja) * 2013-06-13 2015-05-07 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP6238921B2 (ja) * 2014-02-17 2017-11-29 大原薬品工業株式会社 イルベサルタンを含有する錠剤
JP5978335B2 (ja) * 2015-03-11 2016-08-24 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP6199922B2 (ja) * 2015-03-20 2017-09-20 大原薬品工業株式会社 化学的な安定性が向上したイルベサルタン含有錠剤
JP6445923B2 (ja) * 2015-04-22 2018-12-26 ダイト株式会社 イルベサルタン含有錠剤の調製方法
JP6737060B2 (ja) * 2015-09-11 2020-08-05 ニプロ株式会社 イルベサルタンを含有する医薬組成物の製造方法
JP6151413B2 (ja) * 2016-07-25 2017-06-21 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP2017141299A (ja) * 2017-05-24 2017-08-17 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
JP6233911B2 (ja) * 2017-08-22 2017-11-22 大原薬品工業株式会社 化学的な安定性が向上したイルベサルタン含有錠剤
JP2018009032A (ja) * 2017-10-19 2018-01-18 大原薬品工業株式会社 化学的な安定性が向上したイルベサルタン含有錠剤
CN108434112A (zh) * 2018-06-08 2018-08-24 华益药业科技(安徽)有限公司 一种厄贝沙坦片及其制备方法
JP2018168185A (ja) * 2018-07-05 2018-11-01 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
PH12018000390A1 (en) * 2018-11-20 2020-09-28 Novex Science Pte Ltd Carbocysteine and zinc tablet
JP2019203031A (ja) * 2019-09-06 2019-11-28 大日本住友製薬株式会社 溶出が良好なイルベサルタン含有医薬組成物および口腔内崩壊錠
GR1010320B (el) * 2021-08-04 2022-10-11 Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH643457A5 (de) * 1979-02-22 1984-06-15 Sandoz Ag Pharmazeutische praeparate zur behandlung der hypertonie.
DE3744317C1 (de) 1987-12-28 1989-05-24 Rudolf Dr Rer Nat Kuerner Verwendung von Calciumsulfat zur Verbesserung der Fermentierung organischer Abfallstoffe
EP0400835A1 (en) 1989-05-15 1990-12-05 Merck & Co. Inc. Substituted benzimidazoles as angiotensin II antagonists
US5164407A (en) 1989-07-03 1992-11-17 Merck & Co., Inc. Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
TW201738B (no) * 1990-03-20 1993-03-11 Sanofi Co
IL99372A0 (en) * 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
US5155120A (en) * 1991-01-14 1992-10-13 Pfizer Inc Method for treating congestive heart failure
IS1756B (is) 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
EP0502575A1 (en) 1991-03-06 1992-09-09 Merck & Co. Inc. Substituted 1-(2H)-isoquinolinones
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
AU5449194A (en) * 1992-10-26 1994-05-24 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
EP0629408A1 (en) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination of angiotensin converting enzyme inhibitors and AII antagonists
US5541209A (en) * 1994-08-22 1996-07-30 Bristol-Myers Squibb Company Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative
FR2725987B1 (fr) * 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive

Also Published As

Publication number Publication date
CN1144656A (zh) 1997-03-12
NZ286612A (en) 1998-03-25
EP0747050B1 (en) 2003-09-03
HUP9601564A2 (hu) 1998-09-28
EP0747050A1 (en) 1996-12-11
RU2210368C1 (ru) 2003-08-20
RU2181590C2 (ru) 2002-04-27
CA2177772A1 (en) 1996-12-08
NZ329547A (en) 1998-06-26
CN1149083C (zh) 2004-05-12
AU702651B2 (en) 1999-02-25
CA2177772C (en) 2007-04-10
NO962387D0 (no) 1996-06-06
DK1275391T3 (da) 2011-07-11
EP0747050B2 (en) 2013-02-13
HU9601564D0 (en) 1996-08-28
CZ163496A3 (en) 1996-12-11
KR100442719B1 (ko) 2004-10-08
ATE503478T1 (de) 2011-04-15
DE69629755T2 (de) 2004-07-01
TW442301B (en) 2001-06-23
HUP9601564A3 (en) 2000-12-28
HK1002384A1 (en) 1998-08-21
NO310495B1 (no) 2001-07-16
ES2205000T3 (es) 2004-05-01
EP1275391B1 (en) 2011-03-30
RU2001130903A (ru) 2004-02-27
PT1275391E (pt) 2011-06-30
PL184893B1 (pl) 2003-01-31
PT747050E (pt) 2003-12-31
DE69629755T3 (de) 2013-08-08
PL314670A1 (en) 1996-12-09
AU5476396A (en) 1996-12-19
DE69629755D1 (de) 2003-10-09
AR002350A1 (es) 1998-03-11
IL118309A (en) 2003-06-24
EP1275391A1 (en) 2003-01-15
HU229369B1 (en) 2013-11-28
IL118309A0 (en) 1996-09-12
CZ291532B6 (cs) 2003-03-12
JP3162626B2 (ja) 2001-05-08
DK0747050T3 (da) 2003-12-15
NO310393B1 (no) 2001-07-02
NO962387L (no) 1996-12-09
JPH08333253A (ja) 1996-12-17
ES2363127T3 (es) 2011-07-21
SG49956A1 (en) 1998-06-15
NO20004743D0 (no) 2000-09-22
DK0747050T4 (da) 2013-05-21
KR970000232A (ko) 1997-01-21
ES2205000T5 (es) 2013-05-30
ATE248594T1 (de) 2003-09-15
DE69638348D1 (de) 2011-05-12
MX9602103A (es) 1997-09-30
ZA964337B (en) 1997-11-28
AR054782A2 (es) 2007-07-18

Similar Documents

Publication Publication Date Title
DK1275391T3 (da) Farmaceutiske sammensætninger indeholdende irbesartan og et diuretikum
NO20021172D0 (no) Farmasöytisk sammensetning
CY2005007I2 (el) Φαρμακευτικες συνθεσεις που περιεχουν δαριφενακινη
IS4706A (is) Lyfjasamsetningar
IS1947B (is) Setin bensýlamínópíperidín efnasambönd og lyfjablöndur þeirra
DE69618587D1 (de) Chinazoline und pharmazeutische zusammensetzungen
FI973243L (fi) Uusi farmaseuttinen yhdistelmä
FI944978L (fi) Syklosporiinijohdannaista sisältävä farmaseuttinen koostumus
HUP9602196A3 (en) Sulfonyl- and sulfinyl-benzoyl-guanidine derivatives and pharmaceutical compositions thereof
DE69614407D1 (de) Pharmazeutische zusammensetzungen
LV11727A (lv) Farmaceitiska kompozicija
FI973229A0 (fi) Uusi farmaseuttinen koostumus
NO975365L (no) Benzopyraner og farmasöytiske sammensetninger inneholdende dem
FI973280L (fi) Farmaseuttinen koostumus
PT850048E (pt) Granulos farmaceuticos
KR970001311A (ko) 에틸 아미도 플루오렌 유도체 및 이를 함유한 약제조성물
NO964309D0 (no) Farmasöytisk sammensetning
BR9605220A (pt) Gonadotropinas e composiçao farmacêutica
IL118384A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing them
KR970008018U (ko) 장제용 위패
TR199501179A2 (tr) Modüler birimler
UA1292S (uk) Таблетка фармацевтична
NO973261L (no) Fremgangsmåte og farmasöytiske blandinger utnyttende desmetylselegilin
BR7501590U (pt) Sinalizador modular e luminoso
SE9500250D0 (sv) Portionstabletter

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees